CHF-6366   Click here for help

GtoPdb Ligand ID: 12165

Synonyms: CHF6366 | compound 29 [PMID: 35901125]
Compound class: Synthetic organic
Comment: CHF-6366 is a dual pharmacology muscarinic receptor antagonist and β2 receptor agonist (MABA) [1]. It was designed to be an inhaled agent for the treatment of respiratory diseases that provides sustained exposure in the lung, but which is rapidly metabolised and eliminated from the systemic circulation.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 5
Rotatable bonds 19
Topological polar surface area 180.27
Molecular weight 764.35
XLogP 5.25
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(N[C@@H](c1ccccc1)c1cccc(c1)OCc1cc(nn1C)C(=O)OCCCCNC[C@@H](c1ccc(c2c1ccc(=O)[nH]2)O)O)O[C@H]1CN2CCC1CC2
Isomeric SMILES O=C(O[C@@H]1C2CCN(CC2)C1)N[C@@H](c1ccccc1)c1cc(OCc2cc(C(=O)OCCCCNC[C@H](O)c3c4ccc(=O)[nH]c4c(O)cc3)nn2C)ccc1
InChI InChI=1S/C42H48N6O8/c1-47-30(23-34(46-47)41(52)54-21-6-5-18-43-24-36(50)32-12-14-35(49)40-33(32)13-15-38(51)44-40)26-55-31-11-7-10-29(22-31)39(28-8-3-2-4-9-28)45-42(53)56-37-25-48-19-16-27(37)17-20-48/h2-4,7-15,22-23,27,36-37,39,43,49-50H,5-6,16-21,24-26H2,1H3,(H,44,51)(H,45,53)/t36-,37-,39-/m0/s1
InChI Key YWSIONULMMKTSJ-UZGNFBRWSA-N
No information available.
Summary of Clinical Use Click here for help
Chiesi Farmaceutici pursued CHF-6366 as a clinical candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), although development beyond the initial phase 1/2 study appears to have been discontinued.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03378648 A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 Phase 1/Phase 2 Interventional Chiesi Farmaceutici S.p.A.